Pharmacokinetics and Safety of Selumetinib Granule Formulation in Children With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (SPRINKLE; phase I/II).

Journal:

Journal of Clinical Oncology

Published:

2026-01-28

DOI:

10.1200/jco-25-01447

Affiliations:

13

Authors:

12

Go to article

Institutions	Authors	Share
Alexion - Spain, Spain	2.000000	0.17
IRCCS Carlo Besta Neurological Institute, Italy	1.000000	0.08
University Medical Center Hamburg-Eppendorf (UKE), UHH, Germany	1.000000	0.08
University Children's Hospital Tübingen, Uni Tübingen, Germany	1.000000	0.08
SJD Barcelona Children's Hospital​ for Maternal and Child Health, BMA, Spain	1.000000	0.08
Alexion Pharmaceuticals, Inc., United States of America (USA)	1.000000	0.08
AstraZeneca Spain, Spain	1.000000	0.08
Alexion Pharma UK LTD, United Kingdom (UK)	1.000000	0.08
Merck & Co, United States of America (USA)	1.000000	0.08
Charité - University Medicine Berlin, Germany	1.000000	0.08
Children's Hospital of Philadelphia (CHOP), United States of America (USA)	0.500000	0.04
University of Pennsylvania (Penn), United States of America (USA)	0.500000	0.04

Interested in Oncology and Carcinogenesis?